NCT03829891View on ClinicalTrials.gov

Study for Beinaglutide Versus Glargine Therapy in Glycemic Variability of Type 2 Diabetes Mellitus

NACompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 7, 2018

Primary Completion Date

December 31, 2019

Study Completion Date

December 4, 2020

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Beinaglutide

"1. Beinaglutide for 8 weeks,~2. Beinaglutide + glargine for 8 weeks(only the subjects whose blood glucose not reach the standard )"

DRUG

glargine

"1. Glargine for 8 weeks,~2. Glargine+Beinaglutide for 8 weeks(only the subjects whose blood glucose not reach the standard )"

Trial Locations (2)

710016

Chang'an Hospital, Xi'an

710025

Shaanxi Aerospace Hospital, Xi'an

All Listed Sponsors
lead

Xijing Hospital

OTHER

NCT03829891 - Study for Beinaglutide Versus Glargine Therapy in Glycemic Variability of Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter